| Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud Bmj 344, 2012 | 1070 | 2012 |
| Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials T Vilsbøll, M Christensen, AE Junker, FK Knop, LL Gluud Bmj 344, 2012 | 1070 | 2012 |
| Medication review in hospitalised patients to reduce morbidity and mortality M Christensen, A Lundh The Cochrane Library, 2016 | 456 | 2016 |
| Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans M Christensen, L Vedtofte, JJ Holst, T Vilsbøll, FK Knop Diabetes 60 (12), 3103-3109, 2011 | 352 | 2011 |
| Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies S Calanna, M Christensen, JJ Holst, B Laferrere, LL Gluud, T Vilsbøll, ... Diabetologia 56, 965-972, 2013 | 304 | 2013 |
| Benefits and harms of sodium-glucose co-transporter 2 inhibitors in patients with type 2 diabetes: a systematic review and meta-analysis H Storgaard, LL Gluud, C Bennett, MF Grøndahl, MB Christensen, ... PLoS One 11 (11), e0166125, 2016 | 272 | 2016 |
| Regulation of glucagon secretion by incretins JJ Holst, M Christensen, A Lund, J De Heer, B Svendsen, U Kielgast, ... Diabetes, Obesity and Metabolism 13, 89-94, 2011 | 194 | 2011 |
| Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes S Calanna, M Christensen, JJ Holst, B Laferrère, LL Gluud, T Vilsbøll, ... Diabetes Care 36 (10), 3346-3352, 2013 | 176 | 2013 |
| Evidence of extrapancreatic glucagon secretion in man A Lund, JI Bagger, NJ Wewer Albrechtsen, M Christensen, M Grøndahl, ... Diabetes 65 (3), 585-597, 2016 | 170 | 2016 |
| Glucagon and type 2 diabetes: the return of the alpha cell A Lund, JI Bagger, M Christensen, FK Knop, T Vilsbøll Current diabetes reports 14, 1-7, 2014 | 149 | 2014 |
| Separate and combined glucometabolic effects of endogenous glucose-dependent insulinotropic polypeptide and glucagon-like peptide 1 in healthy individuals LS Gasbjerg, MM Helsted, B Hartmann, MH Jensen, MBN Gabe, ... Diabetes 68 (5), 906-917, 2019 | 142 | 2019 |
| Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans MJ Bak, NW Albrechtsen, J Pedersen, B Hartmann, M Christensen, ... European Journal of Endocrinology 170 (4), 529-538, 2014 | 136 | 2014 |
| Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes E Jimenez-Solem, MH Rasmussen, M Christensen, FK Knop Curr Opin Mol Ther 12 (6), 790-7, 2010 | 124 | 2010 |
| Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. M Christensen, FK Knop, JJ Holst, T Vilsboll IDrugs: the investigational drugs journal 12 (8), 503-513, 2009 | 123 | 2009 |
| Glucose-dependent insulinotropic polypeptide inhibits bone resorption in humans A Nissen, M Christensen, FK Knop, T Vilsbøll, JJ Holst, B Hartmann The Journal of Clinical Endocrinology & Metabolism 99 (11), E2325-E2329, 2014 | 117 | 2014 |
| Lixisenatide for type 2 diabetes mellitus M Christensen, FK Knop, T Vilsbøll, JJ Holst Expert opinion on investigational drugs 20 (4), 549-557, 2011 | 113 | 2011 |
| Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes MB Christensen, S Calanna, JJ Holst, T Vilsbøll, FK Knop The Journal of Clinical Endocrinology & Metabolism 99 (3), E418-E426, 2014 | 104 | 2014 |
| Glucose-dependent insulinotropic polypeptide: blood glucose stabilizing effects in patients with type 2 diabetes MB Christensen, S Calanna, JJ Holst, T Vilsbøll, FK Knop The Journal of Clinical Endocrinology & Metabolism 99 (3), E418-E426, 2014 | 104 | 2014 |
| Effects of combined GIP and GLP-1 infusion on energy intake, appetite and energy expenditure in overweight/obese individuals: a randomised, crossover study NC Bergmann, A Lund, LS Gasbjerg, ECE Meessen, MM Andersen, ... Diabetologia 62, 665-675, 2019 | 99 | 2019 |
| Species‐specific action of (Pro3) GIP–a full agonist at human GIP receptors, but a partial agonist and competitive antagonist at rat and mouse GIP receptors AH Sparre‐Ulrich, LS Hansen, B Svendsen, M Christensen, FK Knop, ... British journal of pharmacology 173 (1), 27-38, 2016 | 93 | 2016 |
